A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

This study has been completed.
Sponsor:
Information provided by:
Adherex Technologies, Inc.
ClinicalTrials.gov Identifier:
NCT00264433
First received: December 12, 2005
Last updated: August 3, 2007
Last verified: August 2007

December 12, 2005
August 3, 2007
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00264433 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201)

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin. This study will examine the clinical activity of ADH-1.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Neoplasms
Drug: ADH -1 (Exherin™)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Signed written informed consent
  • Male and female patients > or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists
  • Histologically proven advanced and/or metastatic solid tumor of one of the following histologies:

    • non-small cell lung cancer (squamous or non-squamous histology),
    • gastroesophageal carcinoma (squamous or adenocarcinoma histology),
    • renal cell carcinoma,
    • hepatocellular carcinoma,
    • adrenocortical carcinoma
  • Measurable disease
  • Immunohistochemical evidence of N-cadherin expression (at least 1+ positive) in archived or fresh tumor tissue
  • Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and electrocardiogram (ECG)

Exclusion Criteria:

  • Receipt of ADH-1 prior to this clinical study
  • Chemotherapy, radiotherapy, or any other investigational drug within 30 days before study entry
  • History of spinal cord compression, or history of primary brain tumor(s) or brain metastases (known or suspected) unless any lesions have completely resolved following appropriate treatment and there has been no recurrence for at least 6 months
  • History of tumors that have shown clinically significant evidence of active bleeding (e.g., gross hemoptysis, hematemesis, hematuria, melena, or bleeding superficial tumor) within 12 weeks before study entry
  • Stroke, major surgery, or other major tissue injury within 30 days before study entry
  • History of:

    • uncontrolled congestive heart failure,
    • coronary artery disease, or life threatening arrhythmias;
    • myocardial infarction less than 12 months prior to study entry;
    • significant ECG abnormalities; or
    • known hypercoagulable states
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00264433
Adherex Protocol # AHX-01-201
Not Provided
Not Provided
Adherex Technologies, Inc.
Not Provided
Not Provided
Adherex Technologies, Inc.
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP